← Back to Search

Other

HMPL-760 for Mantle Cell Lymphoma

Phase 1
Waitlist Available
Research Sponsored by Hutchison Medipharma Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
ECOG performance status of 0 or 1;
Histologically confirmed NHL or CLL with disease progression or intolerance to either ≥2 prior regimens. Patients with CLL/SLL and indolent NHL must meet criteria for systemic therapy. Patients with gastric extranodal MZL who are H. pylori positive must have failed H. pylori eradication therapy.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from 1st dose of study drug to the time of progressive disease, assessed up to 36 months
Awards & highlights

Study Summary

This trial is testing a new drug, HMPL-760, on patients who have already been treated for a type of cancer called CLL/SLL or NHL. They're testing how safe and tolerable the drug is, as well as its efficacy.

Eligible Conditions
  • Mantle Cell Lymphoma
  • Follicular Lymphoma
  • Chronic Lymphocytic Leukemia
  • Lymphoplasmacytic Lymphoma
  • Richter Syndrome
  • Waldenstrom Macroglobulinemia
  • Non-Hodgkin's Lymphoma
  • Medial Collateral Ligament

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from 1st dose of study drug to the time of progressive disease, assessed up to 36 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and from 1st dose of study drug to the time of progressive disease, assessed up to 36 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of AEs/SAEs
Incidence of DLTs
MTD
+1 more
Secondary outcome measures
Chemokines
Clinical Benefit Rate (CBR)
Duration of Response (DoR)
+4 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: TreatmentExperimental Treatment1 Intervention
All patients to receive HMPL-760 daily.

Find a Location

Who is running the clinical trial?

Hutchison Medipharma LimitedLead Sponsor
100 Previous Clinical Trials
13,549 Total Patients Enrolled
HutchmedLead Sponsor
26 Previous Clinical Trials
4,864 Total Patients Enrolled
Vijay Jayaprakash, MBBS, PHDStudy DirectorHutchison Medipharma Limited
1 Previous Clinical Trials
75 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA greenlit HMPL-760 for public consumption?

"HMPL-760's safety is rated 1, since this Phase 1 trial has only limited data to show efficacy and its effects on health."

Answered by AI

Are there plentiful locations within the United States hosting this medical experiment?

"The present recruitment phase requires 12 medical sites, located in New Orleans, The Woodlands, Kansas City and other locations. To minimize the burden of travel for patients, it is recommended to select the closest centre available should you choose to participate."

Answered by AI

Is it feasible to join this trial at the present time?

"As indicated by clinicaltrials.gov, this medical trial is in the process of recruiting participants. This investigation was initially publicized on February 15th 2022 and recently updated on November 2nd 2022."

Answered by AI

What are the prominent goals of this medical research?

"The main metric of this trial, taken over a period between the first dose and 30 days after last dose is Adverse Event/Serious Aedverse Events Incidence. Secondary measurements include Objective Response Rate (ORR), Duration of Response (DoR) and Progression-Free Survival (PFS). ORR gauges partial or better response to therapy; DoR marks time from initial respone until progression or relapse; PFS measures survival without disease advance."

Answered by AI

How many participants are taking part in this research project?

"To complete this clinical trial, the sponsor is looking to enrol 168 participants that meet the inclusion criteria. Several medical centres are involved, such as Tulane Cancer Center in New Orleans and Renovatio Clinical in The Woodlands."

Answered by AI
~0 spots leftby Apr 2025